HP
ITRM

Hound Partners’s Iterum Therapeutics ITRM Stock Holding History

Hound Partners’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,300
Closed -$129K – 33
2018
Q3 		$129K Buy
+1,300
New +$170K ﹤0.01% 32

Other funds holding ITRM

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
NA
Neuburgh Advisers Los Angeles, California $3.22B AUM 3.74% 1-Year Est. Return
FCM
Flinton Capital Management Philadelphia, Pennsylvania $3.22B AUM 4.75% 1-Year Est. Return

Hound Partners's ITRM Position: Q4 2018 in Review

Hound Partners sold out of Iterum Therapeutics (ITRM) in Q4 2018, closing a stake of 1,300 shares — an estimated $129K sold.

Hound Partners first reported a position in ITRM in Q3 2018 and held it in 1 quarter. The position peaked at $129K in Q3 2018. 22 funds tracked by Wall St. Rank hold ITRM as of Q4 2018.

  • Hound Partners reported no remaining Iterum Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Hound Partners sold 1,300 Iterum Therapeutics shares in Q4 2018, an estimated $129K.
  • Hound Partners first reported a position in Iterum Therapeutics in Q3 2018 and held it in 1 quarter.
  • Hound Partners's Iterum Therapeutics position peaked at $129K in Q3 2018.
  • 22 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q4 2018.

Based on Hound Partners's 13F filing for Q4 2018, filed 14 Feb 2019.